Dr. Reshma Kewalramani, M.D., is the Chief Executive Officer and President of Vertex Pharmaceuticals, a Fortune 500 global biotechnology company. She became CEO on April 1, 2020, making her the first female CEO of a large US biotech company. Born in Bombay, India in 1973, Kewalramani immigrated to the United States with her family when she was 11 years old. She graduated summa cum laude and Phi Beta Kappa in 1998 from Boston University’s seven-year liberal arts/medical education program.

She completed her internship and residency in internal medicine at Massachusetts General Hospital and her fellowship in nephrology at the combined program of Massachusetts General Hospital and Brigham and Women’s Hospital. In 2015, she graduated from Harvard Business School’s General Management Program.cIn 2004, she transitioned to the biotech industry, spending 12 years at Amgen where she ultimately served as vice president and head of the U.S. medical organization. She joined Vertex in 2017 as Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs.

Kewalramani has dedicated her career to improving patient lives through new medicine development. Dr. Kewalramani has been instrumental in expanding Vertex’s portfolio, particularly in cystic fibrosis, overseeing the approval of breakthrough therapies such as TRIKAFTA/KAFTRIO​. Dr. Kewalramani’s leadership philosophy centers on patient-centric innovation and fostering the next generation of scientists. Under her leadership, Vertex aims to develop transformative therapies for various diseases, enhancing patient outcomes and continuing its legacy of scientific excellence. She is passionate about diversity in STEM and serves on several boards, including the Biomedical Science Careers Program and RIZE Massachusetts​. Indiaspora is proud to have Dr. Reshma Kewalramani on our Business Leaders 2.0 List.